Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.
Manon N G J A BraatSander C EbbersAhmed A AlsultanAtal O NeekRutger C G BruijnenMaarten L J SmitsJoep de BruijneMarnix G E H LamArthur Johannes Anthonius Theodorus BraatPublished in: Diagnostics (Basel, Switzerland) (2023)
In this single-center, retrospective review, P/UDCA use did not reduce liver toxicity in patients with metastatic liver disease. The whole non-tumorous liver-absorbed dose was the only significant factor for hepatotoxicity. No standardized international guidelines or supporting evidence exist for PPM in radioembolization.